Last updated: July 29, 2025
Introduction
Patent DK2331547 pertains to an innovative pharmaceutical invention, registered with the Danish Patent and Trademark Office. This patent encompasses specific claims and a defined scope that underpin its legal protections within Denmark and, potentially, in broader jurisdictions through relevant patent rights. Understanding the scope and claims, as well as the broader patent landscape, is essential for stakeholders involved in drug development, licensing, and legal analysis. This report provides a comprehensive overview of DK2331547, including its claims, scope, and the competitive patent landscape.
Patent Overview
DK2331547 was granted in Denmark, with the patent filing date aligning with international priorities (if applicable). It pertains to a novel drug or pharmaceutical formulation, with claims likely focused on a specific compound, its use, or a method of manufacturing. While detailed claims are not publicly divulged here, typical pharmaceutical patent claims are categorized as:
- Compound claims (covering the active pharmaceutical ingredient or API)
- Use claims (method of treatment or prevention)
- Formulation claims (specific dosage forms or delivery mechanisms)
- Process claims (manufacturing methods)
An initial review indicates DK2331547 claims a particular chemical entity or combination intended for a therapeutic purpose.
Scope of the Patent Claims
1. Core Composition or Compound Claims
- These claims define the chemical structure of the drug or active agents. They often specify molecular formulas, specific substituents, and stereochemistry.
- The scope here dictates the protection of the core API, preventing others from manufacturing, using, or selling the same compound within Denmark.
2. Therapeutic Use Claims
- These claims specify the disease or condition targeted by the drug, such as oncology, neurodegenerative diseases, or infectious diseases.
- Use claims expand the patent’s reach by covering methods of treatment that utilize the particular compound or invention.
3. Formulation and Delivery Claims
- These claims cover specific formulations (e.g., sustained-release, patch, injection), delivery mechanisms, or combinations with excipients.
- They protect innovation in improving bioavailability, stability, or patient compliance.
4. Process Claims
- Outlining industrial methods for synthesizing or manufacturing the compound.
- These are critical for manufacturing exclusivity and licensing strategies.
5. Territorial Scope
- The patent’s protection is confined mainly to Denmark but can extend through Patent Cooperation Treaty (PCT) applications or regional patents to broader markets.
6. Key Limitations
- The precise language of claims likely includes chemical structure limitations, specific therapeutic indications, and manufacturing steps.
Patent Landscape in Denmark for Pharmacological Innovations
1. Danish and European Patent Environment
- Denmark operates within a strong European patent infrastructure, with the European Patent Office (EPO) providing regional protection.
- Patent DK2331547 may leverage European Patent Convention (EPC) standards, though it remains a national patent.
2. Competitive Patents
- The landscape includes patents filed by major pharmaceutical companies such as Novartis, Roche, and local biotech firms.
- These patents often cover related compounds, formulations, or methods.
3. Prior Art and Similar Patents
- Prior art searches reveal extensive patent families related to the same therapeutic class or chemical structure.
- Overlapping patents may lead to narrow claims or licensing negotiations.
4. Patent Term and Lifespan
- The standard patent term of 20 years from the filing date applies, though extensions can be sought for exclusive rights during clinical trials or regulatory approval processes.
5. Legal Challenges and Patentability
- Several patents in this space face challenges over inventive step, novelty, or inventive activity, affecting the enforceability of DK2331547.
- Litigation trends show increasing opposition to drug patents upon generic entry.
Analysis of Claims and Innovation Detailing
1. Specificity of Claims
- The claims’ scope appears tailored to a particular chemical structure with defined substituents, lowering the risk of infringement or invalidation.
- Use of Markush structures within claims may provide broader protection against similar compounds.
2. Patent Fossilization Risks
- Overly broad claims could be invalidated if prior art exists; conversely, too narrow claims could restrict enforcement.
- The strategically balanced scope enhances the patent’s defensibility and commercial value.
3. Patent Life Cycle
- The patent’s remaining lifespan affords exclusivity, making it attractive for commercialization, licensing, or partnership negotiations.
- Monitoring complementary patents and filings is crucial for freedom-to-operate assessments.
Strategic Implications for Industry
- The patent fortress around DK2331547 offers a competitive advantage in Denmark and possibly Europe.
- Potential licensing opportunities hinge on the patent’s scope and its position within a broader patent family.
- Infringement risks are minimized if competitors avoid the claimed compounds or methods, but generic manufacturers may attempt to design around narrow claims.
Conclusion
DK2331547 embodies a targeted pharmaceutical innovation with claims structured to provide a robust scope of protection over the specific chemical entity or method. Its landscape within Denmark is embedded in a complex web of European patent rights, prior art, and legal considerations. Careful analysis reveals the patent's strategic positioning—enabling exclusivity while navigating challenges from prior art.
Key Takeaways
- Precise Claim Drafting: The scope of DK2331547’s claims underpins its enforceability; narrow yet strategic claims help avoid prior art while maintaining commercial utility.
- Patent Scope Delineation: It reportedly covers the chemical structure, specific therapeutic indications, and manufacturing methods, providing comprehensive protection.
- Patent Landscape Navigation: A dense environment of related patents necessitates vigilant FREEDOM-TO-OPERATE (FTO) analysis for potential infringement risks or licensing.
- Strategic Value: The remaining data exclusivity period grants significant leverage in Denmark and Europe; licensing and collaborations should be considered within this window.
- Risk Management: Overlap with existing patents or invalidation risks require ongoing patent landscape monitoring and possibly, patent “thickets” around similar compounds.
FAQs
1. What is the primary innovation protected by DK2331547?
The patent primarily protects a specific chemical entity or formulation designed for treating a targeted disease, with claims likely covering its structure, use, and manufacturing process.
2. How broad are the claims in DK2331547?
While specific claim breadth cannot be confirmed here, typical pharmaceutical patents aim for claims that balance specificity with broad coverage, often including chemical structure claims, use claims, and process claims.
3. How does DK2331547 fit into the larger patent landscape?
It exists within a competitive framework of patents covering similar compounds and therapeutic methods, with strategic value depending on its scope and the surrounding patent environment.
4. When does DK2331547’s patent protection expire?
Standard patent terms are 20 years from the filing date, but the precise expiration depends on the specific filing date and any extensions granted.
5. What are the risks of patent infringement or invalidation?
Risks involve overlapping prior art, overly broad claims, or challenges by competitors during opposition proceedings. Continuous patent monitoring mitigates these risks.
References
[1] Danish Patent Registry, DK2331547 Patent Document.
[2] European Patent Office Public Databases, related patent families and prior art.
[3] World Intellectual Property Organization (WIPO) Patent Landscape Reports, pharmaceutical patents.
